Single-dose administration of the gonadotropin-releasing hormone antagonist, Nal-Lys (antide) to healthy men

24Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Objective: To evaluate the ability the Nal-Lys GnRH antagonist ([N-Ac-Nal (2)1, 4ClDPhe2, D3Pal3, Lys (Nic)5, D-Lys(Nic)6, Lys (iPr)8, D- Ala10] to suppress gonadotropins and T in humans and to assess its duration of action and its local effects. Design: Placebo-controlled clinical study. Setting: A university community. Subjects: Seven normal male volunteers. Interventions: We administered single injections of Nal-Lys (0, 10, 25, and 50 μg/kg body weight). Blood samples were collected before and at frequent time intervals after injection. Results: Nal-Lys caused only minor local effects. At the higher doses (25 and 50 μg/kg), serum LH and T levels were suppressed to 50% to 70% of baseline; serum FSH levels were suppressed to 70% to 80% of baseline, and levels of all three hormones returned to basal values within 24 hours after injection. Conclusions: In humans, Nal-Lys has similar potency and duration of action to other antagonists and produces fewer local side effects. However, the utility of Nal-Lys is limited by formulation difficulties; current efforts are directed at improving the formulation in order to explore the potential clinical uses of this peptide.

Cite

CITATION STYLE

APA

Bagatell, C. J., Conn, P. M., & Bremner, W. J. (1993). Single-dose administration of the gonadotropin-releasing hormone antagonist, Nal-Lys (antide) to healthy men. Fertility and Sterility, 60(4), 680–685. https://doi.org/10.1016/S0015-0282(16)56222-0

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free